A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Status
- RECRUITING
- Phase
- PHASE2
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
- Status
- COMPLETED
- Phase
- PHASE2
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
- Status
- RECRUITING
- Phase
- PHASE1
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE1
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- NA
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
- Status
- COMPLETED
- Phase
- PHASE2